ARTICLE | Finance
Third Rock-launched Pliant is latest biotech to climb on public debut
Three more biotechs hope to price deals on NASDAQ this week
June 3, 2020 11:05 PM UTC
Pliant joins a slew of recent biotechs that have seen substantial first-day gains.
The fibrosis company closed up $5.30 (33%) to $21.30 on Wednesday after raising $144 million through the sale of 9 million shares at $16, the high end of its range. The upsized offering gives Pliant Therapeutics Inc. (NASDAQ:PLRX) a postmoney valuation of $547.9 million. ...
BCIQ Company Profiles